For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $1.59 in the last session, down -3.05% from day before closing price of $1.64. In other words, the price has decreased by -$3.05 from its previous closing price. On the day, 0.82 million shares were traded. ZNTL stock price reached its highest trading level at $1.655 during the session, while it also had its lowest trading level at $1.55.
Ratios:
We take a closer look at ZNTL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.99 and its Current Ratio is at 7.99. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 114695456 and an Enterprise Value of -143811856. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 0.42. Its current Enterprise Value per Revenue stands at -5.353 whereas that against EBITDA is 0.844.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.76, which has changed by -0.5181818 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $5.44, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 14.26%, while the 200-Day Moving Average is calculated to be -21.47%.
Shares Statistics:
According to the various share statistics, ZNTL traded on average about 954.23K shares per day over the past 3-months and 786280 shares per day over the past 10 days. A total of 72.14M shares are outstanding, with a floating share count of 57.22M. Insiders hold about 20.68% of the company’s shares, while institutions hold 73.26% stake in the company. Shares short for ZNTL as of 1753920000 were 4708124 with a Short Ratio of 4.93, compared to 1751241600 on 5070961. Therefore, it implies a Short% of Shares Outstanding of 4708124 and a Short% of Float of 8.1499994.
Earnings Estimates
At present, 7.0 analysts are actively evaluating the performance of Zentalis Pharmaceuticals Inc (ZNTL) in the stock market.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.27 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.48 and -$2.13 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.84, with 7.0 analysts recommending between -$1.15 and -$2.28.
